TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 11/01/21

My portfolio, built specifically for my retirement ~20+ years from now, rides the September downturn in the market back under $400k. Some massive risk-on portfolio restructuring including more Bitcoin as I prepare for the seasonal Santa Claus and Bitcoin run. Making monthly contri...

Takeda Pharmaceutical Company Limited (TAK) Q2 2022 Results Conference Call October 28, 2021 05:30 AM ET Company Participants Christopher O’Reilly - Global Head, IR & Global Finance Christophe Weber - President and CEO Andy Plump - President Research and Development Costa Saroukos ...

My portfolio, built specifically for my retirement ~20+ years from now, rides the September downturn in the market back under $400k. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable reti...

Glenview Capital Management’s 13F portfolio value increased marginally from $5.90B to $5.96B this quarter. The number of positions increased from 63 to 64. They increased ViacomCBS and Global Payments while reducing Cigna, DXC Technology, Takeda Pharmaceuticals, and HCA Healthc...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September

John Paulson’s 13F portfolio value remained steady at $4.35B this quarter. Paulson & Company's added DiDi Global & increased Occidental Petroleum while reducing Viatris and dropping Takeda. The top three positions are at 45% of the portfolio. For further detai...

Takeda Pharmaceutical's (NYSE:TAK) late-stage study of its drug pevonedistat plus chemotherapy azacitidine failed as an initial treatment to prevent death in patients with a rare form of bone cancer. The phase 3 trial, dubbed PANTHER (Pevonedistat-3001), evaluated pevonedistat in combination&...

My portfolio, built specifically for my retirement ~20+ years from now, eclipses new highs as the market continues to grind higher. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retir...

Sold out of the China uncertainty as I await a potential major flushing in those stocks if China decides to make an example out of a company like DiDi. A hit to Arrowhead Pharmaceuticals presented a buying opportunity while Bitcoin shows signs of wanting to break out. A portfolio ...

Takeda Pharmaceutical Co Ltd (TAK) Q1 2022 Earnings Conference Call July 30, 2021, 06:00 ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development Constantine Saroukos - CFO M...